Verdiva Bio - About the company
Verdiva Bio is a series A company based in London (United Kingdom), founded in 2024. It operates as a Developer of therapies for obesity, cardiometabolic disorders, and related complications. Verdiva Bio has raised $411M in funding from General Atlantic and Forbion. The company has 374 active competitors, including 116 funded and 106 that have exited. Its top competitors include companies like argenx, Tenaya Therapeutics and Vor Biopharma.
Company Details
Developer of therapies for obesity, cardiometabolic disorders, and related complications. It offers VRB-101 an oral GLP-1 peptide, multiple amylin molecules and other undisclosed programs for enhanced efficacy, improved tolerability, and healthier weight loss.
- Website
- verdivabio.com
- Email ID
- *****@verdivabio.com, *****@verdivabio.com
- Phone Number
- +1 **********
Key Metrics
Founded Year
2024
Location
London, United Kingdom
Stage
Series A
Total Funding
$411M in 1 round
Latest Funding Round
Investors
Ranked
46th among 374 active competitors
Similar Companies
Sign up to download Verdiva Bio's company profile
Verdiva Bio's funding and investors
Verdiva Bio has raised a total funding of $411M over 1 round. Its latest funding round was a Series A round on Jan 09, 2025 for $*****. 7 investors participated in its latest round. Verdiva Bio has 7 institutional investors.
Here is the list of recent funding rounds of Verdiva Bio:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jan 09, 2025 | 8000930 | Series A | 5137437 | 8793631 | 6971051 | 2383040 |
Access funding benchmarks and valuations. Sign up today!View details of Verdiva Bio's funding rounds and investors
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Verdiva Bio's Competitors and alternates
Top competitors of Verdiva Bio include argenx, Tenaya Therapeutics and Vor Biopharma. Here is the list of Top 10 competitors of Verdiva Bio, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Developer of antibody-based drugs to treat autoimmune diseases and cancer | $61.9M | 72/100 | ||
2nd | Tenaya Therapeutics 2016, San Francisco (United States), Public | Developer of regenerative and gene therapeutics for heart failure | $248M | 70/100 | |
3rd |  Vor Biopharma 2019, Cambridge (United States), Public | Developer of therapeutics to treat acute myeloid leukemia | $152M | 68/100 | |
4th | Esperion Therapeutics 1998, Ann Arbor (United States), Public | Developer of lipoprotein cholesterol (LDL-C) lowering therapies | $107M | 67/100 | |
5th | Kiniksa Pharmaceuticals 2015, Lexington (United States), Public | Developer of therapeutics for multiple diseases treatment | $320M | 67/100 | |
6th | Cellino 2017, Cambridge (United States), Series A | Developer of autologous cell therapies | $125M | 65/100 | |
7th | Edgewise Therapeutics 2017, Boulder (United States), Public | Developer of therapeutics for skeletal and cardiac muscle diseases | $145M | 65/100 | |
8th | Horizon Therapeutics 2008, Dublin (Ireland), Acquired | Developer of drugs for treating rare and autoimmune diseases | $61.8M | 64/100 | |
9th | MyoKardia 2012, San Francisco (United States), Acquired | Developing drugs for treating genetic heart diseases | $98M | 63/100 | |
10th | Kailera 2024, Waltham (United States), Series B | Developer of therapies for treating obesity and related conditions | $1B | 62/100 | |
46th | Verdiva Bio 2024, London (United Kingdom), Series A | Developer of therapies for obesity, cardiometabolic disorders, and related complications | $411M | 53/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Verdiva Bio's competitors? Click here to see the top ones
Verdiva Bio's Investments and acquisitions
Verdiva Bio has made no investments or acquisitions yet.
News related to Verdiva Bio
Filter this listMedia has covered Verdiva Bio for a total of 5 events in the last 1 year, 3 of them have been about company updates and 1 about partnerships.
•
Verdiva Bio Completes Enrollment for VRB-101 Obesity Phase 2b StudyBusiness Wire•Feb 24, 2026•Verdiva Bio
•
•
Verdiva Bio and MitoRx Developing Next-Gen Obesity TherapiesBioSpace•Feb 19, 2026•Verdiva Bio, MitoRx Therapeutics
•
Kailera Therapeutics Secures $600M to Advance Obesity Drug Similar to ZepboundBioPharmaDive•Oct 14, 2025•Helicore Biopharma, Verdiva Bio, Kailera, Isomorphic Labs and 10 others
•
Eikon raises $351M in one of the year’s largest biotech venture roundsBioPharmaDive•Feb 26, 2025•Eikon, Merck, Seven and Eight Biopharmaceuticals, Verdiva Bio and 2 others
•
Two billion-plus deals among January’s largest announced transactionsInsider Media•Feb 03, 2025•Dowlais, Diversified Energy, GSK, Petershill Partners and 24 others
•
Verdiva Bio Raises Over $410M in Series A FinancingFinSMEs•Jan 13, 2025•Verdiva Bio, Orbimed, Logos, Lilly
•
Verdiva Bio joins weight loss race with $411M Series APitchBook•Jan 10, 2025•Verdiva Bio, Forbion, General Atlantic, Orbimed and 6 others
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Verdiva Bio
Explore our recently published companies
- OrthoRenew - Mumbai based, 2024 founded, Unfunded company
- Ilmberger - Germany based, Unfunded company
- Mycloset.me - 2025 founded, Unfunded company
- Carlweiske - Germany based, Unfunded company
- Praxisenglisch - Unfunded company
- Hospital Quiron Bizkaia - Madrid based, Unfunded company
